Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis

Journal of Urology

Volumn 185, Issue 4, 2011, Pages 1344-1349

  Khan, Shahid ^a   Game, Xavier ^a,c   Kalsi, Vinay ^a   Gonzales, Gwen ^a   Panicker, Jalesh ^a   Elneil, Sohier ^a   Apostolidis, Apostolos ^a,d   Hamid, Rizwan ^a   Dasgupta, Prokar ^a,b   Kessler, Thomas M ^a,e   Fowler, Clare J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c CHU RANGUEIL   (France)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

botulinum toxin type A; multiple sclerosis; quality of life; urinary bladder, neurogenic; urinary incontinence

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN A; MUSCARINIC RECEPTOR BLOCKING AGENT; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; BLADDER EMPTYING; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DETRUSOR MUSCLE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; LIMB WEAKNESS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE PROCEDURE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REPEATED DRUG DOSE; RETREATMENT; SUPRAPUBIC CATHETERIZATION; SYMPTOMATOLOGY; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE INCONTINENCE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RETREATMENT; TIME FACTORS; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 79952695484     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.12.002     Document Type: Article

References (19)

1. Compston A and Coles A: Multiple sclerosis. Lancet 2002; 359: 1221.
2. Confavreux C, Aimard G and Devic M: Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281.
3. de Seze M, Ruffion A, Denys P et al: The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13: 915.
4. Fowler CJ, Panicker JN, Drake M et al: A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 470.
5. Kalsi V, Gonzales G, Popat R et al: Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007; 62: 452.
6. Harper M, Popat R, Dasgupta R et al: A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003; 92: 325.
7. Kalsi V, Apostolidis A, Popat R et al: Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006; 49: 528.
8. Uebersax JS, Wyman JF, Shumaker SA et al: Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 1995; 14: 131.
9. Grosse J, Kramer G and Stohrer M: Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653.
10. Reitz A, Stohrer M, Kramer G et al: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510.
11. Del Popolo G, Filocamo MT, Li Marzi V et al: Neurogenic detrusor overactivity treated with English botulinum toxin a: 8-year experience of one single centre. Eur Urol 2008; 53: 1013.
12. Schulte-Baukloh H, Schobert J, Stolze T et al: Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 2006; 25: 110.
13. Giannantoni A, Mearini E, Del Zingaro M et al: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009; 55: 705.
14. Schurch B, Stohrer M, Kramer G et al: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692.
15. Kessler TM, Khan S, Panicker J et al: Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009; 113: 1046.
16. Fisk JD, Brown MG, Sketris IS et al: A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry 2005; 76: 58.
17. Comperat E, Reitz A, Delcourt A et al: Histologic features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006; 50: 1058.
18. Karsenty G, Denys P, Amarenco G et al: Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/ neurogenic overactive bladder: a systematic literature review. Eur Urol 2008; 53: 275.
19. Popat R, Apostolidis A, Kalsi V et al: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174: 984.